MedPath

Epidemiological Data on Mast Cell Pathologies in France

Recruiting
Conditions
Mast Cell Disorder
Registration Number
NCT06186856
Lead Sponsor
Imagine Institute
Brief Summary

Mast cell disorders constitute a heterogeneous group of diseases, including :

* mastocytosis, i.e. cutaneous, indolent and severe forms of the disease, such as aggressive mastocytosis and mast cell leukemia) ;

* mast cell-associated diseases such as mast cell activation syndrome (idiopathic, secondary or clonal), affecting both children and adults.

No epidemiological data are currently available in France.

In France, medical care of mast cell disorders is mainly provided by a rare disease network (CEREMAST), whose CRMR is located at the Necker Enfants Malades hospital in Paris. A total of 20 centers are located throughout France.

Our aim is to use this network to study patients suffering from these diseases. The overall aim of the study is to improve the understanding, diagnosis, prognosis, recognition and management of patients with mastocytosis.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
13000
Inclusion Criteria
  1. Children from birth and adults of any age

  2. With one of the following mast cell diseases:

    • Mastocytoses (cutaneous, systemic and sarcomas) Defined according to the WHO 2016 classification
    • Mast cell activation syndromes (idiopathic, secondary and clonal)
    • Other mast cell activation disorders (MCAD-NOS), Defined according to the Vienna classification
    • Pre-mastocytosis or MMC (1 to 2 criteria according to WHO 2016 classification).
  3. Managed in France in a rare disease reference, constitutive or competence center (CEREMAST) with DGOS labelization.

Exclusion Criteria
  1. Opposition of the patient or his/her parents to participation in the study.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Epidemiology of mast cell disorders in France assessed by statistics on the prevalence on the various types of mast cell disordersData 2010 - 2038
Epidemiology of mast cell disorders in France assessed by statistics on the incidence on the various types of mast cell disordersData 2010 - 2038
Secondary Outcome Measures
NameTimeMethod
Characteristics of mast cell disease assessed by diagnostic criteriaData 2010 - 2038
Evolution of mast cell disease assessed by progression of skin lesionsData 2010 - 2038
Patient characteristicsData 2010 - 2038

age, gender, personal and family medical history

Characteristics of mast cell disease assessed by symptoms of diseaseData 2010 - 2038
Evolution of mast cell disease assessed by progression to aggressive formData 2010 - 2038
Patient follow-up assessed by overall survivalData 2010 - 2038
Types of treatment used on mastocytosis and any associated hemopathyData 2010 - 2038
Evolution of mast cell disease assessed by appearance of new symptomsData 2010 - 2038
Characteristics of mast cell disease assessed by type of diseaseData 2010 - 2038
Evolution of mast cell disease assessed by associated hemopathyData 2010 - 2038
Patient follow-up assessed by occurrence of other medical events in the patientData 2010 - 2038
Tolerance of treatment used on mastocytosis and any associated hemopathyData 2010 - 2038
Efficacy of treatment used on mastocytosis and any associated hemopathyData 2010 - 2038

Trial Locations

Locations (15)

CHU AMIENS site sud

🇫🇷

Amiens, France

Chu Angers

🇫🇷

Angers, France

Chu - Besancon

🇫🇷

Besançon, France

Chu - Caen

🇫🇷

Caen, France

Chu - Clermont Ferrand

🇫🇷

Clermont-Ferrand, France

Chru Lille

🇫🇷

Lille, France

Chu - Limoges

🇫🇷

Limoges, France

Chu - La Timone - Marseille

🇫🇷

Marseille, France

CHU de NANCY

🇫🇷

Nancy, France

Chu - Nantes

🇫🇷

Nantes, France

Hôpital Universitaire Pitié Salpetrière

🇫🇷

Paris, France

Hôpital Necker-Enfants malades

🇫🇷

Paris, France

Chu - Rennes

🇫🇷

Rennes, France

CHU Réunion sud - Saint Pierre

🇫🇷

Saint-Pierre, France

Chru - Strasbourg

🇫🇷

Strasbourg, France

© Copyright 2025. All Rights Reserved by MedPath